Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Yellow Fever Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination

NCT05859490
View directory record Official record
Conditions
Yellow Fever, Immunization; Infection
Interventions
17D
Biological
Lead sponsor
Oregon Health and Science University
Other
Eligibility
20 Years to 49 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination

NCT01244802
View directory record Official record
Conditions
Yellow Fever Vaccine
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2029
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Yellow Fever Virus Vaccine and Immune Globulin Study

NCT00254826
View directory record Official record
Conditions
Viremia
Interventions
YF-VAX® plus saline, 17D YF Vaccine plus Ig,
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial of an Inactivated Yellow Fever Virus Vaccine

NCT05172544
View directory record Official record
Conditions
Yellow Fever
Interventions
HydroVax-002 YFV, Placebo
Biological · Other
Lead sponsor
Najit Technologies, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine

NCT05374317
View directory record Official record
Conditions
Yellow Fever Vaccination Reaction
Interventions
Yellow Fever Vaccine
Biological
Lead sponsor
US Army Medical Research Institute of Infectious Diseases
Federal
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

NCT01488890
View directory record Official record
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Interventions
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
7
States / cities
Alabaster, Alabama • Sacramento, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jun 7, 2026, 4:17 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

NCT04942210
View directory record Official record
Conditions
Yellow Fever, Healthy Volunteers
Interventions
Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
568 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
11
States / cities
Decatur, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

NCT01290055
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water
Biological · Other
Lead sponsor
Sri Edupuganti
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Human Immune Responses to Yellow Fever Vaccination

NCT00694655
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow Fever Vaccine, Leukapheresis, Fine-needle aspiration (FNA)
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

NCT04269265
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow Fever Vaccine
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898
View directory record Official record
Conditions
Dengue
Interventions
YF-17D, TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial of Yellow Fever Inactivated Vaccine

NCT00995865
View directory record Official record
Conditions
Yellow Fever
Interventions
XRX-001 Inactivated yellow fever vaccine, Placebo
Biological
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

NCT07002060
View directory record Official record
Conditions
Yellow Fever Immunization
Interventions
Yellow fever vaccine (live), YF vaccine (live)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 59 Years
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Decatur, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 7, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Yellow Fever Immune Response at Single Cell Resolution

NCT03458780
View directory record Official record
Conditions
Healthy
Interventions
Yellow Fever Vaccine
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 59 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

NCT04142086
View directory record Official record
Conditions
Yellow Fever (Healthy Volunteers)
Interventions
Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine, Yellow fever vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old

NCT03725618
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow Fever 17DD Vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
9 Months to 23 Months
Enrollment
1,788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jun 7, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

NCT00723489
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years to 43 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jun 7, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults

NCT00616356
View directory record Official record
Conditions
Yellow Fever
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Jun 7, 2026, 4:17 PM EDT